Compare · MGRX vs PGNY
MGRX vs PGNY
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.11B, about 295.3x MGRX ($7.1M).
- MGRX has been more active in the news (8 items in the past 4 weeks vs 4 for PGNY).
- PGNY has more recent analyst coverage (25 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Progyny Inc.
- Price
- -
- -
- Market cap
- $7.1M
- $2.11B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 8
- 4
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest MGRX
- SEC Form 8-K filed by Mangoceuticals Inc.
- SEC Form 424B5 filed by Mangoceuticals Inc.
- Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
- SEC Form 4 filed by Mangoceuticals Inc.
- SEC Form 4 filed by Mangoceuticals Inc.
- SEC Form 4 filed by Mangoceuticals Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Mangoceuticals Inc.
- Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Regulation FD Disclosure
- Mangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
Latest PGNY
- SEC Form 4 filed by Progyny Inc.
- Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
- Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
- EVP, GC Swartz Allison sold $101,868 worth of shares (3,903 units at $26.10) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 75,816 units (SEC Form 4)
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,009 units (SEC Form 4) to cover taxes
- Amendment: Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $311,858 worth of shares (11,500 units at $27.12) (SEC Form 4)
- Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)